Erythropoietin Therapy in Peritoneal Dialysis Patients

Stojimirovic B. , Grujic–Adanja G. The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia. Srp Arh Celok Lek 1997; 125: 163–7.

Joske R.A. , McAlister J.M. , Prankerd T.A.J. Isotope investigations of red cell production and destruction in chronic renal disease [Abstract]. Clin Sci 1956; 15: 511.

Fiers W. , Beyaert R. , Declercq W. , Vandenabeele P. More than one way to die: Apoptosis, necrosis and reactive oxygen damage. Oncogene 1999; 18(54): 7719–30.

National Kidney Foundation Dialysis Outcomes Quality Initiative. Clinical practice guidelines for peritoneal dialysis adequacy. Am J Kidney Dis 1997; 30(Suppl 3): S192–240.

Nissenson A.R. Optimal hematocrit in patients on dialysis therapy. Am J Kidney Dis 1998; 32(Suppl 4): S142–6.

Marsh J.T. , Brown W.S. , Wolcott D. , Carr C.R. , Harper R. , Schweitzer S.V. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 1991; 39: 155–63.

Eshbach J. , Glenny R. , Robertson T. , Guthrie M. , Rader B. , Evans R. Normalizing the hematocrit (Hct) in hemodialysis patients (HDP) with EPO improves quality of life (Q/L) and is safe [Abstract]. J Am Soc Nephrol 1993; 4: 425.

Evans R.W. , Radar B. , Manninen D.L. , and the Cooperative Multicenter EPO Clinical Trial Group. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990; 263: 825–30.

Churchill D.N. , Muirhead N. , Goldstein M. , Posen G. , Fay W. , Beecroft M.L. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. Clin Nephrol 1995; 43: 184–8.

Eschbach J.W. , Abdulhadi M.H. , Brown J.K. , Delano B.G. , Downing M.R. , Egrie J.C. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a Phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992–1000.

Paszkowska M. , Jezynska A. , Krol M. , Rokicka– Piotrowicz M. , Kuratowska Z. Zinc protoporphyrin (ZZP) in diagnosis of anemia. Pol Arch Med Wewn 1997; 12: 520–6.

Hastka J. , Lasserre J.J. , Schwarzbeck A. , Hehlmann R. Central role of zinc protoporphyrin in staging iron deficiency. Clin Chem 1994; 40: 768–73.

Tarng D.C. , Huang T.P. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant 1998; 13: 2867–72.

Tarng D.C. , Wei Y.H. , Huang T.P. , Kuo B.I. , Yang W.C. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int 1999; 55: 2477–86.

Paganini E.P. Overview of anemia associated with renal disease: Primary and secondary mechanisms. Semin Nephrol 1989; (1 Suppl 1): 3–8.

Vaziri N.D. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999; 33: 821–8.

Metry G. , Wikström B. , Valind S. , Sandhagen B. , Linde T. , Beshara S. Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients. J Am Soc Nephrol 1999; 10: 854–63.

Besarab A. , Bolton W.K. , Browne J.K. , Egrie J.C. , Nissenson A.R. , Okamoto D.M. The effects of normal versus low hematocrit values in hemodialysis patients with cardiac disease. N Engl J Med 1998; 339: 584–90.

Burkart J.M. , Freedman B.I. , Rocco M.V. The effect of increasing hematocrit on peritoneal transport kinetics. J Am Soc Nephrol 1994; 4: 1726–32.

Gandolfo C. , Battista G. , Viglino G. , Cavalli P. Hematocrit has no effect on peritoneal transport indices. In: Khanna R. , ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1995; 11: 41–4.